DOP2015000111A - Composición de vehículos y formas farmacéuticas de liberación sostenida y aumento de biodisponibilidad de antibacterianos, anticoccidianos y otros fármacos en aves comerciales y cerdos - Google Patents

Composición de vehículos y formas farmacéuticas de liberación sostenida y aumento de biodisponibilidad de antibacterianos, anticoccidianos y otros fármacos en aves comerciales y cerdos

Info

Publication number
DOP2015000111A
DOP2015000111A DO2015000111A DO2015000111A DOP2015000111A DO P2015000111 A DOP2015000111 A DO P2015000111A DO 2015000111 A DO2015000111 A DO 2015000111A DO 2015000111 A DO2015000111 A DO 2015000111A DO P2015000111 A DOP2015000111 A DO P2015000111A
Authority
DO
Dominican Republic
Prior art keywords
composition
vehicles
pharmaceutical forms
pigs
drugs
Prior art date
Application number
DO2015000111A
Other languages
English (en)
Inventor
Lilia Gutierrez Olvera
Héctor Salvador Sumano López
Original Assignee
Univ Nac Autónoma De México
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nac Autónoma De México filed Critical Univ Nac Autónoma De México
Publication of DOP2015000111A publication Critical patent/DOP2015000111A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)

Abstract

La presente invención se refiere a una composición de vehículos y formas farmacéuticas de liberación sostenida y aumento de biodisponibilidad de fármaco para aves y cerdos y procedimiento para su preparación, dicha composición comprende: agentes farmacéuticamente activos, agentes promotores de la biodisponibilidad, polímeros de liberación prolongada del fármaco, colorantes, y saborizantes. La composición de vehículos y formas farmacéuticas de la presente invención optimiza la dosificación del fármaco y genera cepas resistentes de bacterias por optimización de la relación entre farmacocinética/farmacodinamia de fármacos. La composición se presenta en diferentes formas y colores que permiten identificación del producto y mejor aceptación por parte del ave o del cerdo.
DO2015000111A 2012-11-14 2015-05-14 Composición de vehículos y formas farmacéuticas de liberación sostenida y aumento de biodisponibilidad de antibacterianos, anticoccidianos y otros fármacos en aves comerciales y cerdos DOP2015000111A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012013222A MX347401B (es) 2012-11-14 2012-11-14 Composicion de vehiculos y formas farmaceuticas de liberacion sostenida y aumento de biodisponibilidad de antibacterianos, anticoccidianos y otros farmacos en aves comericales y cerdos.

Publications (1)

Publication Number Publication Date
DOP2015000111A true DOP2015000111A (es) 2015-11-15

Family

ID=50731496

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000111A DOP2015000111A (es) 2012-11-14 2015-05-14 Composición de vehículos y formas farmacéuticas de liberación sostenida y aumento de biodisponibilidad de antibacterianos, anticoccidianos y otros fármacos en aves comerciales y cerdos

Country Status (7)

Country Link
US (1) US20160279063A1 (es)
CN (1) CN105050599A (es)
BR (1) BR112015010980A8 (es)
DO (1) DOP2015000111A (es)
MX (1) MX347401B (es)
SV (1) SV2015004970A (es)
WO (1) WO2014077666A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104127429A (zh) * 2014-07-28 2014-11-05 邳州正康生物技术有限公司 一种用于防治畜禽呼吸道疾病的饮水剂及其制备方法
CN105878228B (zh) * 2016-06-27 2018-05-18 河北天元药业有限公司 一种延胡索酸泰妙菌素可溶性粉及其制备方法
WO2019077115A1 (en) * 2017-10-20 2019-04-25 Axichem Ab SYNTHETIC ANALOGUES OF CAPSAICINE AS BIOACTIVATORS
CN107648616A (zh) * 2017-10-27 2018-02-02 四川康四海动物药业有限公司 一种替米考星包合工艺
CN108484693B (zh) * 2018-03-14 2020-08-11 中科荣信（苏州）生物科技有限公司 一种壳寡糖-抗生素偶联物及其制备方法和应用
CN108324694A (zh) * 2018-04-13 2018-07-27 成都乾坤动物药业股份有限公司 一种土霉素缓释片及其制备方法与用途
CN108379593A (zh) * 2018-05-28 2018-08-10 青岛科技大学 一种制备氟苯尼考-壳聚糖/长链羧酸纳米胶束冻干粉的方法
CN109700783A (zh) * 2019-03-04 2019-05-03 江西派尼生物药业有限公司 一种壳聚糖包被替米考星微球的制备方法
CN114533679B (zh) * 2022-01-28 2023-03-14 马超锋 一种磺胺氯哒嗪缓释纳米胶粒及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06321810A (ja) * 1992-09-24 1994-11-22 Bayer Kk 鶏の筋胃破砕力を利用した持効性製剤
GB9500863D0 (en) * 1995-01-17 1995-03-08 Grampian Pharm Ltd Medicated animal foodstuffs
DE10328666A1 (de) * 2003-06-26 2005-01-13 Bayer Healthcare Ag Tabletten enthaltend Geschmacks-und/oder Aromastoffe
WO2007009205A1 (en) * 2005-07-15 2007-01-25 Fisher Feeds Limited Animal feed
CN1969851A (zh) * 2005-11-25 2007-05-30 天津市润拓生物技术有限公司 一种畜禽使用的恩诺沙星结肠靶向丸剂制备方法
US20070209599A1 (en) * 2006-03-10 2007-09-13 Archer-Daniels-Midland Company Methods and compositions for increased productivity in animals
AU2007293068C1 (en) * 2006-09-07 2013-09-19 Boehringer Ingelheim Animal Health USA Inc. Soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations
CN101744772A (zh) * 2008-11-27 2010-06-23 河南农业大学 一种制备兽用药物缓释微粒的方法
CN102648896A (zh) * 2011-02-28 2012-08-29 郑州福源动物药业有限公司 一种畜禽使用的恩诺沙星缓释微丸及其制备方法

Also Published As

Publication number Publication date
MX2012013222A (es) 2014-05-22
BR112015010980A2 (pt) 2017-07-11
BR112015010980A8 (pt) 2019-10-01
SV2015004970A (es) 2017-07-10
CN105050599A (zh) 2015-11-11
MX347401B (es) 2017-04-18
WO2014077666A1 (es) 2014-05-22
US20160279063A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
DOP2015000111A (es) Composición de vehículos y formas farmacéuticas de liberación sostenida y aumento de biodisponibilidad de antibacterianos, anticoccidianos y otros fármacos en aves comerciales y cerdos
BR112014024833A8 (pt) Produto farmacêutico veterinário mastigável macio, processo para a fabricação de um produto, uso de ácido pamóico ou um sal farmaceuticamente aceitável do mesmo, uso de um produto farmacêutico veterinário mastigável macio, e, composição farmacêutica veterinária mastigável macia.
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
TWD179358S (zh) 藥物注射裝置之部分（二）
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
BR112012028788A2 (pt) fabricação de grânulos sem ativos
ES2429422R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
WO2017046215A3 (en) Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrier for converting a neoplastic cell into a non-neoplastic cell and uses thereof
AR093012A1 (es) Composiciones farmaceuticas en polvo, activas, con enmascaramiento del sabor y procesos para su fabricacion
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
WO2010059038A3 (en) Wet granulation of tenofovir, emtricitabine and efavirenz
BR112014009242A2 (pt) nanossuspensão farmacêutica
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp
WO2013018050A3 (en) Dissolution enhanced controlled drug delivery system for poorly water soluble drugs
WO2014043336A3 (en) Tetrandrine pharmaceutical formulations and method
WO2017046219A3 (en) Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrierfor converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2012108631A3 (en) Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof
UY37518A (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
WO2014045307A3 (en) Pharmaceutical composition
PH12014501822A1 (en) Oral formulation comprising lansoprazole and the preparation method thereof
MX2015006217A (es) Tableta dispersable.
ECSP17008187A (es) Formas de dosificación farmacéutica